Lauren Barnes

Lauren Barnes is Senior Vice President, Strategic Market Development & Access for Blueprint Medicines, a commercial stage Boston based precision medicine company focusing on genomically defined cancers, rare diseases and cancer immunotherapy. Ms. Barnes has extensive expertise and experience in pricing, market access, pre-commercialization and managed markets in particular for the US market. She has been involved in launch planning of more than 50 drugs, devices and diagnostics during her career. Prior to her current role Lauren was Vice President at Vertex Pharmaceuticals, SVP Avalere Health and led their Reimbursement & Commercialization practice and has also held various roles at Amgen and the agency that runs the United States Medicare Program, the Centers for Medicare and Medicaid Services.

Ms. Barnes has a BA in Public Health and a MHS in Health Care Policy from Johns Hopkins University. She serves on the board of Ascelia, a Swedish biotech company, as well as Ossium Health, a US biotech company, both of which are developing innovative cancer treatments.